Showing results (431-440 of 520) with videos related to

Sort By:
Pageof 52
Science Translational Medicine|November 27, 2015
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockadePhilipp Müller, Matthias Kreuzaler, Tarik Khan, et al.
Science Advances|June 30, 2023
Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapyOmar S Sarkar, Howard Donninger, Numan Al Rayyan, et al.
Cancer Research|April 17, 2004
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional toleranceAlfred Zippelius, Pascal Batard, Verena Rubio-Godoy, et al.
Spine|April 27, 2026
Relationship between Preoperative Global Sagittal Alignment and Changes in Cervical Alignment Following Lumbar Pedicle Subtraction OsteotomyBruno Verna, Thomas Caffard, Marco D Burkhard, et al.
Nature Immunology|March 14, 2019
Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Nature Communications|May 27, 2017
Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapySandra M Kallert, Stephanie Darbre, Weldy V Bonilla, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Nature Immunology|January 22, 2019
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Immunity|September 29, 2022
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificityRodrigo Vazquez-Lombardi, Johanna S Jung, Fabrice S Schlatter, et al.
Medrxiv : the Preprint Server for Health Sciences|November 19, 2025
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinomaSilvia Guglietta, Anne Bärenwaldt, Anthony Sonrel, et al.
Pageof 52